Nedocromil 2mg/dose inhaler
A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Nedocromil
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Nedocromil
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Part of the Tilade brand family (generic: Nedocromil)
MHRA licensed products
View all licensed products for Nedocromil on the MHRA register
WHO defined daily dose (DDD)
8 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Nedocromil
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
3.3 hours
Mechanism
Nedocromil has been shown to inhibit the in vitro activation of, and mediator re…
Food interactions
None known
Human targets
4 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
3.3 hours
Protein binding
89%
Metabolism
Elimination
70%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 733 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
The rank order of affinities for the leukotrienes is LTD4 >> LTE4 = LTC4 >> LTB4
The rank order of affinities for the leukotrienes is LTC4 = LTD4 >> LTE4
PMID:10514456 PMID:15153520 PMID:2161213 PMID:2176894
Binding of fMLP to the receptor stimulates intracellular calcium mobilization and superoxide anion release .
PMID:15153520 PMID:15210802 PMID:1712023 PMID:2161213
This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system .
PMID:10514456 PMID:1712023
Receptor for TAFA4, mediates its effects on chemoattracting macrophages, promoting phagocytosis and increasing ROS release .
PMID:25109685
Receptor for cathepsin CTSG, leading to increased phagocyte chemotaxis PMID:15210802
Involved in PLA2G3-dependent maturation of mast cells. PLA2G3 is secreted by immature mast cells and acts on nearby fibroblasts upstream to PTDGS to synthesize PGD2, which in turn promotes mast cell maturation and degranulation via PTGDR (By similarity)
ATC R03BC03
ATC R01AC07
ATC S01GX04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Nedocromil
Additional database identifiers
Drugs Product Database (DPD)
1324
ChemSpider
45608
BindingDB
50239990
ZINC
ZINC000003782807
HUGO Gene Nomenclature Committee (HGNC)
HGNC:17451
GenAtlas
CYSLTR1
GeneCards
CYSLTR1
GenBank Gene Database
AF119711
GenBank Protein Database
5353887
Guide to Pharmacology
269
UniProt Accession
CLTR1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:18274
GenAtlas
CYSLTR2
GeneCards
CYSLTR2
GenBank Gene Database
AB038269
GenBank Protein Database
9663958
Guide to Pharmacology
270
UniProt Accession
CLTR2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3826
GenAtlas
FPR1
GeneCards
FPR1
GenBank Gene Database
M37128
GenBank Protein Database
189184
Guide to Pharmacology
222
UniProt Accession
FPR1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9591
GenAtlas
PTGDR
GeneCards
PTGDR
GenBank Gene Database
U31332
GenBank Protein Database
940379
Guide to Pharmacology
338
UniProt Accession
PD2R_HUMAN
International reference pricing
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
Patent information
All patents expired, 1 expired
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: